Biora Therapeutics, Inc. Selling, General and Administrative Expense
Biora Therapeutics, Inc. reported Selling, General and Administrative Expense of $10.65 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2024-11-14
- Biora Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2024-09-30 was $10.65M, a 16.64% decline year-over-year.
- Biora Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2024-06-30 was $8.40M, a 6.18% decline year-over-year.
- Biora Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2024-03-31 was $9.05M, a 8.34% increase year-over-year.
- Biora Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2023-12-31 was $7.23M, a 9.93% decline year-over-year.
- Biora Therapeutics, Inc. selling, general and administrative expense for fiscal 2023 was $37.31M, a 1.91% decline from fiscal 2022.
- Biora Therapeutics, Inc. selling, general and administrative expense for fiscal 2022 was $38.04M, a 48.11% decline from fiscal 2021.
- Biora Therapeutics, Inc. selling, general and administrative expense for fiscal 2021 was $73.30M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2024-09-30 | $10.65M 10-Q · filed 2024-11-14 | $19.05M derived: sum of 2 quarters · filed 2024-11-14 | $28.10M 10-Q · filed 2024-11-14 | $35.33M derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | $8.40M 10-Q · filed 2024-08-12 | $17.45M 10-Q · filed 2024-08-12 | $24.68M derived: sum of 3 quarters · filed 2024-08-12 | $37.45M derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-03-31 | $9.05M 10-Q · filed 2024-05-15 | $16.28M derived: sum of 2 quarters · filed 2024-05-15 | $29.05M derived: sum of 3 quarters · filed 2024-11-14 | $38.01M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-12-31 | $7.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $20.00M derived: sum of 2 quarters · filed 2024-11-14 | $28.95M derived: sum of 3 quarters · filed 2024-11-14 | $37.31M 10-K · filed 2024-04-01 |
| 2023-09-30 | $12.77M 10-Q · filed 2024-11-14 | $21.73M derived: sum of 2 quarters · filed 2024-11-14 | $30.08M 10-Q · filed 2024-11-14 | $38.11M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $8.95M 10-Q · filed 2024-08-12 | $17.31M 10-Q · filed 2024-08-12 | $25.33M derived: sum of 3 quarters · filed 2024-08-12 | $33.48M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $8.36M 10-Q · filed 2024-05-15 | $16.38M derived: sum of 2 quarters · filed 2024-05-15 | $24.53M derived: sum of 3 quarters · filed 2024-05-15 | $32.94M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $8.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $16.17M derived: sum of 2 quarters · filed 2024-04-01 | $24.58M derived: sum of 3 quarters · filed 2024-04-01 | $38.04M 10-K · filed 2024-04-01 |
| 2022-09-30 | $8.15M 10-Q · filed 2023-11-13 | $16.56M derived: sum of 2 quarters · filed 2023-11-13 | $30.01M 10-Q · filed 2023-11-13 | $42.12M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $8.41M 10-Q · filed 2023-08-14 | $21.87M 10-Q · filed 2023-08-14 | $33.98M derived: sum of 3 quarters · filed 2023-08-14 | $52.49M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $13.46M 10-Q · filed 2023-05-15 | $25.57M derived: sum of 2 quarters · filed 2023-05-15 | $44.08M derived: sum of 3 quarters · filed 2023-05-15 | $66.80M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $12.11M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $30.63M derived: sum of 2 quarters · filed 2023-03-30 | $53.34M derived: sum of 3 quarters · filed 2023-03-30 | $73.30M 10-K · filed 2023-03-30 |
| 2021-09-30 | $18.52M 10-Q · filed 2022-11-14 | $41.23M derived: sum of 2 quarters · filed 2022-11-14 | $61.19M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $22.71M 10-Q · filed 2022-08-15 | $42.67M 10-Q · filed 2022-08-15 |